Marc Tessier Lavigne is Director of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 2,434 shares of REGN, which is worth approximately $1.74 Million. The most recent transaction as insider was on Jan 03, 2023, when has been sold 165 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.43K
0% 3M change
0% 12M change
Total Value Held $1.74 Million

Marc Tessier-Lavigne Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 03 2023
BUY
Grant, award, or other acquisition
-
165 Added 6.35%
2,434 Common Stock
Jan 03 2023
BUY
Grant, award, or other acquisition
-
165 Added 6.35%
2,434 Common Stock
Oct 03 2022
SELL
Open market or private sale
$2,593,416 $718.0 p/Share
3,612 Reduced 61.42%
2,269 Common Stock
Oct 03 2022
BUY
Exercise of conversion of derivative security
$1,492,948 $413.33 p/Share
3,612 Added 38.05%
5,881 Common Stock
Sep 30 2022
SELL
Open market or private sale
$2,392,744 $698.0 p/Share
3,428 Reduced 60.17%
2,269 Common Stock
Sep 30 2022
BUY
Exercise of conversion of derivative security
$1,416,895 $413.33 p/Share
3,428 Added 37.57%
5,697 Common Stock
Sep 29 2022
SELL
Open market or private sale
$2,637,749 $694.51 p/Share
3,798 Reduced 62.6%
2,269 Common Stock
Sep 29 2022
BUY
Exercise of conversion of derivative security
$1,569,827 $413.33 p/Share
3,798 Added 38.5%
6,067 Common Stock
Mar 21 2022
SELL
Open market or private sale
$5,132,910 $690.0 p/Share
7,439 Reduced 76.63%
2,269 Common Stock
Mar 21 2022
BUY
Exercise of conversion of derivative security
$2,833,887 $380.95 p/Share
7,439 Added 43.38%
9,708 Common Stock
Mar 17 2022
SELL
Open market or private sale
$5,324,400 $680.0 p/Share
7,830 Reduced 77.53%
2,269 Common Stock
Mar 17 2022
BUY
Exercise of conversion of derivative security
$2,949,483 $376.69 p/Share
7,830 Added 43.67%
10,099 Common Stock
Mar 16 2022
SELL
Open market or private sale
$2,943,675 $675.0 p/Share
4,361 Reduced 65.78%
2,269 Common Stock
Mar 16 2022
BUY
Exercise of conversion of derivative security
$1,631,537 $374.12 p/Share
4,361 Added 39.68%
6,630 Common Stock
Jan 03 2022
BUY
Grant, award, or other acquisition
-
191 Added 7.76%
2,269 Common Stock
Dec 09 2021
SELL
Open market or private sale
$2,516,360 $665.0 p/Share
3,784 Reduced 64.55%
2,078 Common Stock
Dec 09 2021
BUY
Exercise of conversion of derivative security
$1,405,378 $371.4 p/Share
3,784 Added 39.23%
5,862 Common Stock
Sep 13 2021
SELL
Open market or private sale
$8,216,482 $644.43 p/Share
12,750 Reduced 85.99%
2,078 Common Stock
Sep 13 2021
BUY
Exercise of conversion of derivative security
$3,489,293 $273.67 p/Share
12,750 Added 46.23%
14,828 Common Stock
Jan 04 2021
BUY
Grant, award, or other acquisition
-
248 Added 10.66%
2,078 Common Stock

Also insider at

DNLI
Denali Therapeutics Inc. Healthcare
MT

Marc Tessier Lavigne

Director
South San Francisco, CA

Track Institutional and Insider Activities on REGN

Follow REGENERON PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN